GlassScriptPhysician profile
Salih Selek
NPI 1376933804
$1,310.92
in general payments reported to CMS, 2019-2025
14 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $569 · 2024: $533 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $333.75 | 2023-2024 | Qelbree, Qelbree |
| Abbvie INC. | $243.49 | 2023-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $118.36 | 2023-2024 | Rexulti, Abilify Maintena |
| Livanova USA, INC. | $113.04 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Lundbeck LLC | $99.23 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $89.60 | 2023-2024 | Invega Sustenna, Invega Trinza, Invega |
| Takeda Pharmaceuticals U.S.A., INC. | $60.10 | 2023-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $53.30 | 2023-2025 | Fanapt, Hetlioz |
| Corium, LLC | $47.08 | 2023 | Azstarys |
| Neurocrine Biosciences, INC. | $46.96 | 2023-2024 | Ingrezza |
| Brainsway USA INC | $45.62 | 2023-2024 | Brainsway Deep Tms System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.57 | 2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $20.45 | 2023 | Jornay Pm |
| Axsome Therapeutics, INC. | $19.37 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salih Selek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.